25 September 2020: Clinical Research
Clinical Characteristics and Risk Factors of Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients in Beijing, China: A Retrospective Study
Aibin Wang 1ABCDE* , Guiju Gao 1ABE* , Sa Wang 1ABDEF* , Meiling Chen 2C* , Fang Qian 1B , Weiming Tang 3BD , Yanli Xu 1B , Rui Song 1B , Liwei Zhuang 4B , Xiaoyang Ma 5B , Tianwei Zhao 1B , Xiaodi Guo 4B , Wei Li 4B , Xudong Wang 6B , Baoliang Li 6B , Chun Hu 6B , Zhihai Chen 1ADE* , Fujie Zhang 1ADE*DOI: 10.12659/MSM.925974
Med Sci Monit 2020; 26:e925974
Table 3 Laboratory and radiologic findings of COVID cases in Beijing, China.
| Clinical characteristics | All patients (n=130) | Non-ARDS (n=104) | ARDS (n=26) | P |
|---|---|---|---|---|
| WBC, Median (range) – 10/L | 4.45 (3.50–5.49) | 4.45 (3.55–5.19) | 4.40 (3.19–6.10) | 0.662 |
| 51/129 (39.53) | 39/103 (37.86) | 12/26 (46.15) | 0.440 | |
| Lym count, Median (range) – 10/L | 1.07 (0.72–1.50) | 1.18 (0.94–1.57) | 0.60 (0.42–0.77) | 0.000 |
| >1.0×10/L, No. (%) | 76/129 (58.91) | 73/103 (70.87) | 3/26 (11.54) | |
| 0.5–1.0×10/L, No. (%) | 41/129 (31.78) | 28/103 (27.18) | 13/26 (50.00) | 0.000 |
| 12/129 (9.30) | 2/103 (0.99) | 10/26 (38.46) | ||
| Ccr, Median (range) – ml/min | 112.2 (82.2–135.2) | 116.6 (84.5–137.2) | 107.1 (71.4–120.1) | 0.092 |
| 43/126 (34.1) | 33/102 (32.4) | 10/24 (41.7) | 0.388 | |
| Cr, Median (range) – umol/l | 68.5 (55.85–82.10) | 68.00 (55.80–80.70) | 69.55 (55.60–88.45) | 0.557 |
| >104 umol/l, No. (%) | 5/129 (3.88) | 5/103 (4.85) | 0 | 0.564 |
| ALT, Median (range) – u/l | 25.80 (18.45–37.95) | 24.80 (17.20–36.70) | 34.5 (21.48–54.68) | 0.020 |
| >40 u/l, No. (%) | 29/129 (22.48) | 18/103 (17.47) | 10/26 (38.46) | 0.020 |
| LDH, Median (range) – u/l | 227 (189–310) | 218 (188–283) | 305 (195–373) | 0.026 |
| >250 u/l, No. (%) | 49/117 (41.88) | 34/92 (36.96) | 15/25 (60.00) | 0.058 |
| CK, Median (range) – u/l | 66.90 (46.20–105.90) | 66.00 (48.40–103.00) | 71.10 (29.35–190.50) | 0.842 |
| >198 u/l, No. (%) | 12/129 (10.26) | 6/103 (9.09) | 6/26 (11.54) | 0.020 |
| CK-MB, Median (range) – u/l | 16.00 (13.00–21.3) | 15.50 (12.90–18.80) | 15.90 (13.20–22.80) | 0.309 |
| >25 u/l, No. (%) | 9/126 (7.14) | 4/91 (4.40) | 5/25 (20.00) | 0.021 |
| CRP, Median (range) – mg/dl | 23.70 (5.00–53.10) | 15.40 (4.30–34.00) | 102.00 (45.50–120.63) | 0.000 |
| >5 mg/dl, No. (%) | 96/129 (74.42) | 71/103 (68.93%) | 25/26 (96.15%) | 0.004 |
| PT, Median (range) – s | 12.30 (11.70–13.40) | 12.10 (11.60–13. 25) | 13.15 (12.50–13.60) | 0.001 |
| >12.5 s, No. (%) | 57/127 (44.88) | 38/101 (37.62) | 19/26 (73.08) | 0.001 |
| FIB, Median (range) – mg/dl | 343.00 (230.00–405.00) | 327 (221–387) | 415 (305–468) | 0.000 |
| >400 mg/dl, No. (%) | 33/127 (25.98) | 19/101 (18.81) | 14/26 (53.85) | 0.000 |
| Lung inflammation No. (%) | 125 (96.15) | 99 (96.12) | 26 (100) | 0.698 |
| Bilateral lung inflammation No. (%) | 71 (54.62) | 45 (43.27) | 26 (100) | 0.000 |
| CD4+T lymphocyte count, Median (range) – cells/ul | 537 (384–713.5) | 537 (404–717) | 471 (273–705) | 0.000 |
| 64/89 (71.91) | 49/69 (71.01) | 15/20 (75.00) | 0.727 | |
| CD8+T lymphocyte count, Median (range) – cells/ul | 331 (187.5–576) | 409 (257–624) | 170 (127–273) | 0.192 |
| 41/89 (46.07) | 24/69 (34.78) | 17/20 (85.00) | 0.000 | |